Sign In
Buy SYRE
$98.33
-3.17 (-3.12%)
At Close: Jul 31, 2026
Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting
03:29pm, Tuesday, 01'st Oct 2024
Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of 2024. SPY001 is an a4b7 inhibitor being developed to target IBD like Crohn's
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
08:00am, Tuesday, 01'st Oct 2024
WALTHAM, Mass. , Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, r
Spyre Therapeutics to Participate in Upcoming Investor Conference
04:47pm, Tuesday, 10'th Sep 2024
WALTHAM, Mass. , Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combi
Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 07'th Aug 2024
Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, a
Preclinical data for SPY001 demonstrate the potential for improved dosing over standard of care, including the potential for dosing every eight or twelve weeks compared to dosing every two weeks for s
Spyre Therapeutics Announces Grants of Inducement Awards
05:23pm, Monday, 03'rd Jun 2024
WALTHAM, Mass. , June 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
08:30am, Wednesday, 29'th May 2024
WALTHAM, Mass. , May 29, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
07:30am, Wednesday, 15'th May 2024
WALTHAM, Mass. , May 15, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:02pm, Thursday, 09'th May 2024
SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity study and remains on track to begin first-in-human studies in the second qua
Spyre Therapeutics Announces Grants of Inducement Awards
05:00pm, Friday, 03'rd May 2024
WALTHAM, Mass. , May 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering,
Spyre Therapeutics Announces Grants of Inducement Awards
05:00pm, Monday, 01'st Apr 2024
WALTHAM, Mass. , April 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineerin
Spyre Therapeutics Announces $180 Million Private Placement
08:00am, Monday, 18'th Mar 2024
WALTHAM, Mass. , March 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutic
Spyre Therapeutics Announces Grants of Inducement Awards
05:25pm, Friday, 01'st Mar 2024
WALTHAM, Mass. , March 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineerin
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
04:05pm, Thursday, 29'th Feb 2024
Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the symbol "SYRE" SPY001, an anti-α4β7 anti
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
07:30am, Monday, 26'th Feb 2024
WALTHAM, Mass. , Feb. 26, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineerin
